First Surgery with OssiGraft Prime Highlights its Exceptional Utility
31 July 2024 - 6:44AM
Business Wire
Ossium Health, a bioengineering company that entered the
orthobiologics field in 2023, announced the first surgery using its
next-generation viable bone matrix, OssiGraft Prime™. The launch of
this innovative product represents a significant leap forward in
orthopedic biologics, offering surgeons and patients meaningful
advantages compared to traditional options.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240730242333/en/
OssiGraft Prime builds upon the success of Ossium’s established
OssiGraft™ viable bone matrix. Like the original OssiGraft product,
OssiGraft Prime boasts an unmatched safety profile that leverages
Ossium’s industry-leading donor screening, processing, and
decontamination protocols, minimizing the risk of infection and
disease transmission. OssiGraft donors are far younger than other
bone allografts, with a median age of 35 and maximum age of 55. Due
to its vertebral bone source, OssiGraft also contains a uniquely
high composition of cancellous bone, which promotes faster bone
regeneration compared to legacy bone allografts that are rich in
cortical bone.
This next-generation product incorporates innovative processing
advancements, resulting in a more cohesive product with a gum-like
consistency precisely engineered to meet the demands of orthopedic
and spine surgeons. By upgrading to OssiGraft Prime, surgeons can
experience optimized handling properties unlike any other viable
bone matrix on the market, enabling them to precisely sculpt and
apply the graft in the intended location with unprecedented
precision and efficiency. The product reliably stays in place and
maintains its integrity during post-surgical irrigation.
“OssiGraft Prime is by far the best product on the market. I
actually said ‘wow!’ out loud in the OR when I handled it in
surgery for the first time,” said Dr. Jason Piraino, a leader and
educator in foot and ankle surgery. “This product exceeded my
expectations. It's moldable and stays exactly where you want it,
which makes it ideal for minimally invasive surgery.”
The first surgery with OssiGraft Prime, an arthroscopic ankle
fusion, required the graft to be precisely shaped and placed
through a narrow incision, demonstrating the product’s unique
value. Surgeons working with OssiGraft Prime benefit from its
ability to consistently fill odd-shaped gaps and tight spaces,
allowing them to push the boundaries of possibility in orthopedic
procedures.
“The successful first surgery using OssiGraft Prime is a
testament to our unwavering commitment to building a healthier
future,” said Kevin Caldwell, CEO, Co-Founder & President of
Ossium Health. “With OssiGraft Prime, we bridged our innovative
product development and tightly controlled manufacturing processes
from cell therapies to orthopedic biologics, drawing on our unique
expertise to deliver a product that represents a new standard of
excellence in the OR. We’re extremely proud of OssiGraft Prime and
its potential to drive improvements in bone healing and overall
patient outcomes.”
OssiGraft Prime is now available nationwide to orthopedic
surgeons that are ready to upgrade their tools and unleash new
possibilities in their practice.
About Ossium Health
Ossium Health is a bioengineering company that leverages its
proprietary organ donor bone marrow banking platform to develop
stem cell therapies for patients with life-threatening blood and
immune diseases. Founded in 2016, the company is led by Kevin
Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief
Science Officer, Co-Founder & EVP. Ossium Health’s
manufacturing facility is registered with the FDA and its
laboratory is certified under the Clinical Laboratory Improvement
Amendment (CLIA).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730242333/en/
Sales Jacob Carstensen Ossium Health, Inc. 415-513-5535
products@ossiumhealth.com
Press Jane Griffin Ossium Health, Inc. 415-513-5535
press@ossiumhealth.com